|
Research Note Directory
Neurobiological Technologies, Inc.
Symbol: NTII
Exchange: NASDAQ
05/20/2003. NTII: Maintain Buy Rating Despite Disappointing
Memantine Diabetic Neuropathy Trial Results
(PDF Version)
04/23/2003. Some Analysts Misconstrue Forest Labs Confr.
Call; Leads to Wide NTII Volatility
(PDF Version)
03/03/2003. NTII - Raising Price Target to $10; Memantine
Regulatory Progress Proceeding
(PDF Version)
12/12/2002. Positive Initial Memantine Results in First Ever US Clinical Trial for Combination Therapy in Treating Alzheimers Disease
(PDF Version)
12/6/2002. Price Up and Rating Reduced to Buy; New $8 Price Target Set Over 6 - 9 Months
(PDF Version)
9/12/2002. Forest Laboratories Announces Positive Results for Phase III NTII Memantine Study
(PDF Version)
8/8/2002. NTII's Memantine NDA Filed In US For Treatment of Moderate to Severe Alzheimer's Disease
(PDF Version)
5/31/2002. NTII Raised to Strong Buy Rating on European Approval
(PDF Version)
Disclaimer
|